Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2020 ( 4 )

2019 ( 28 )

2018 ( 28 )

2017 ( 38 )

Custom range...

Search Results: 1 - 10 of 22891 matches for " Pedro Enrique Dorlhiac; "
All listed articles are free for downloading (OA Articles)
Page 1 /22891
Display every page Item
Triagem para o tratamento ambulatorial da neutropenia febril
Bellesso, Marcelo;Costa, Silvia Figueiredo;Chamone, Dalton Alencar Fischer;Llacer, Pedro Enrique Dorlhiac;
Revista Brasileira de Hematologia e Hemoterapia , 2010, DOI: 10.1590/S1516-84842010000500014
Abstract: febrile neutropenia is a frequent and potentially fatal adverse event of chemotherapy. nowadays, febrile neutropenia is considered an emergency and it is known that prompt infusion of antibiotics decreases mortality. several studies demonstrated that febrile neutropenia is a heterogeneous group of diseases and that factors such as outpatient status, no hypotension, no dehydration, no chronic obstructive pulmonary disease, no symptoms, no previous fungal infection and age < 60 years are protective factors against serious complications as demonstrated by the multinational association for supportive care in cancer (mascc). these data show that outpatient treatment and early discharge is safer and much research has shown lower costs for outpatient treatment in low-risk patients with febrile neutropenia. the aim of this work is to review and discuss tools (in particular the mascc index) for safe screening of febrile neutropenia for outpatient treatment in addition to demonstrate results of research.
Comparison of catheter-related infection risk in two different long-term venous devices in adult hematology-oncology patients
Pracchia, Luís Fernando;Dias, Lúcia Cristina Santos;Dorlhiac-Llacer, Pedro Enrique;Chamone, Dalton de Alencar Fisher;
Revista do Hospital das Clínicas , 2004, DOI: 10.1590/S0041-87812004000500012
Abstract: purpose: infection is the leading complication of long-term central venous catheters, and its incidence may vary according to catheter type. the objective of this study was to compare the frequency and probability of infection between two types of long-term intravenous devices. methods: retrospective study in 96 onco-hematology patients with partially implanted catheters (n = 55) or completely implanted ones (n = 42). demographic data and catheter care were similar in both groups. infection incidence and infection-free survival were used for the comparison of the two devices. results: in a median follow-up time of 210 days, the catheter-related infection incidence was 0.2102/100 catheter-days for the partially implanted devices and 0.0045/100 catheter-days for the completely implanted devices; the infection incidence rate was 46.7 (ci 95% = 6.2 to 348.8). the 1-year first infection-free survival ratio was 45% versus 97%, and the 1-year removal due to infection-free survival ratio was 42% versus 97% for partially and totally implanted catheters, respectively (p <.001 for both comparisons). conclusion: in the present study, the infection risk was lower in completely implanted devices than in partially implanted ones.
Aspergillary bronchopneumonia: an unusual cause of atelectasis and asphyxia in a leukemic patient
Velloso, Elvira Deolinda Rodrigues Pereira;Martinez, Gracia Aparecida;Dorlhiac-Llacer, Pedro Enrique;Chamone, Dalton Alencar Fischer;
Sao Paulo Medical Journal , 1994, DOI: 10.1590/S1516-31801994000400004
Abstract: a 22-year-old man in his first relapse of t-acute lymphoblastic leukemia developed fever and a pulmonary infiltrate after 23 days of granulocytopenia. although having been under amphotericin b for 10 days, productive purulent cough ensued, with right lobe atelectasis and acute ventilatory failure that resolved after the elimination of a thick gelatinous bronchial plug. sputum cultures yielded candida albicans and staphylococcus epidermidis, and microscopic examination of the sputum plug disclosed aspergillus hyphae. the patient died 9 days after, of a disseminated aspergillus infection, confirmed by necropsy.
Quimioimunoterapia como primeira linha de tratamento da leucemia linfóide cr?nica: uma vis?o crítica
Llacer, Pedro E. Dorlhiac;
Revista Brasileira de Hematologia e Hemoterapia , 2005, DOI: 10.1590/S1516-84842005000400013
Abstract: there is no solid clínical evidence to the effect that the association of fludarabine, cyclophosphamide and rituximab should be the new gold standard for the initial treatment of chronic lymphocytic leukemia patients. this combination induces a high complete remission rate that in turn is associated with an increased probability of survival. prospective randomized trials are needed to see how efficient this combination truly is.
The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
Monika Conchon,Sabri S. Sanabani,Israel Bendit,Carla Luana Dinardo,Lucia Dias,Dalton de Alencar Fischer Chamone,Pedro Enrique Dorlhiac-Llacer,Frederico Luiz Dulley
Journal of Transplantation , 2009, DOI: 10.1155/2009/357093
Abstract: We describe the response of imatinib as lifesaving treatment of chronic myeloid leukemia (CML) relapse in seven patients who underwent allogeneic bone marrow transplantation (alloBMT) at our institution over a period of 4 years. Retrospective analysis of their medical records revealed that a mean age at transplant was 45.2 years. The median time to diagnosis was 7.4 years after transplant. At relapse, four, two, and one patients were classified as having hematologic, major molecular, and cytogenetic relapse, respectively. At imatinib initiation, five had CML in a chronic phase, while one patient was diagnosed as having accelerated phase and blast crisis. All these patients could be evaluated for the therapeutic efficacy. At a mean of follow-up of 1.9 years of therapy, all evaluable patients achieved major molecular response without compromising safety. Consistent with available data, our results indicate that imatinib is safe and effective treatment option for patients with relapse after BMT.
Hemolytic disease of the newborn due to anti-U
Novaretti, Marcia Cristina Zago;Jens, Eduardo;Pagliarini, Thiago;Bonifácio, Silvia Le?o;Dorlhiac-Llacer, Pedro Enrique;Chamone, Dalton de Alencar Fischer;
Revista do Hospital das Clínicas , 2003, DOI: 10.1590/S0041-87812003000600006
Abstract: anti-u is a rare red blood cell alloantibody that has been found exclusively in blacks. it can cause hemolytic disease of the newborn and hemolytic transfusion reactions. we describe the case of a female newborn presenting a strongly positive direct antiglobulin test due to an igg antibody in cord blood. anti-u was recovered from cord blood using acid eluate technique. her mother presented positive screening of antibodies with anti-u identified at delivery. it was of igg1 and igg3 subclasses and showed a titer of 32. monocyte monolayer assay showed moderate interaction of fc receptors with maternal serum with a positive result (3.1%). the newborn was treated only with 48 hours of phototherapy for mild hemolytic disease. she recovered well and was discharged on the 4th day of life. we conclude that whenever an antibody against a high frequency erythrocyte antigen is identified in brown and black pregnant women, anti-u must be investigated.
COSTA Angela Aparecida,INENAMI Marta,JUAREZ Edmundo,LLACEN Pedro Dorlhiac
Revista do Instituto de Medicina Tropical de S?o Paulo , 1997,
Abstract: Three 10 μg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/l, seroconversion 95.3%) and reactogenicity (no incapacitating side effects)
Estudo de grupos sangüíneos em doadores de sangue caucasóides e negróides na cidade de S?o Paulo
Novaretti, Marcia C. Z.;Dorlhiac-Llacer, Pedro E.;Chamone, Dalton A.F.;
Revista Brasileira de Hematologia e Hemoterapia , 2000, DOI: 10.1590/S1516-84842000000100004
Abstract: despite the fact mulattos (individuals resulting from admixture of caucasian and black individuals) represent one of the most common racial mixed individuals not only in brazil but in many other countries, there is little information regarding the distribution of blood groups among them. we studied 2,462 blood donors classified as caucasian, mulattos e blacks according to their anthropological characteristics as well as to their ancestry information. phenotype frequencies were studied in the abo, mns, p, rh, lutheran, kell, lewis, duffy e kidd blood group systems. we did not find significant statistically difference between blacks and mulattos for the majority of the blood groups systems here reported, excepting of p1 positive, dccee, le(a-b-), js(a+b+), js(a-b+), fy(a-b-), fy(a+b+) e fy(a-b+). on the other he there was a significant difference between caucasian and blacks for the following red blood cells phenotypes: a, b, m+n-s+s-, m+n-s-s+, p1 positivo, ddccee, dccee, dccee, dccee, dccee, k+k+, k-k+, kp(a-b+), kp(a+b+), js(a-b+), js(a+b-), le(a-b+), le(a-b-), fy(a-b+), fy(a+b+), fy(a-b-), jk(a+b-), jk(a+b+) e jk(a-b+). conclusion: as expected, the results for the mulattos group were intermediate between caucasian and blacks, with strong negroid influence.
Controle de qualidade interno de regentes em imunohematologia: aspectos práticos
Novaretti, Marcia C. Z.;Bueno, Valdecir J.;Dorlhiac-Llacer, Pedro E.;Chamone, Dalton A. F.;
Revista Brasileira de Hematologia e Hemoterapia , 2002, DOI: 10.1590/S1516-84842002000400005
Abstract: one of the main objectives of transfusion medicine is to promote safe transfusion. continuous improvement involves the standardization of techniques used for quality control of reagents, adequate equipment evaluation and its maintenance and staff training. quality control of reagents is critical for achieving reliable results in immunohematological testing. in brazil, as far as we know, there are no minimum requirements for immunohematological reagent guidelines. this paper has the purpose of describing practical aspects of quality control in imunohematology, as well as providing information on the most common immunohematological reagents available on the brazilian market.
Controle de qualidade interno de regentes em imunohematologia: aspectos práticos
Novaretti Marcia C. Z.,Bueno Valdecir J.,Dorlhiac-Llacer Pedro E.,Chamone Dalton A. F.
Revista Brasileira de Hematologia e Hemoterapia , 2002,
Abstract: A hemoterapia tem buscado incessantemente o aumento da seguran a transfusional. Para tanto tem envolvido, dentre outros, a padroniza o de testes que comprovem a qualidade dos reagentes utilizados nos servi os hemoterápicos, as análises, o uso e a manuten o de equipamentos apropriados e treinamento de funcionários. O controle de qualidade é essencial e indispensável para a obten o de resultados confiáveis nos ensaios para os quais se destinam. Até o momento, n o há descri o pré-estabelecida dos requisitos mínimos para os reagentes utilizados nos testes imuno-hematológicos pelo Ministério da Saúde. Este trabalho tem por objetivo apresentar os aspectos práticos que envolvem o controle de qualidade em imuno-hematologia, além de informa es básicas sobre os principais reagentes imuno-hematológicos disponíveis no mercado brasileiro.
Page 1 /22891
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.